Air Products, Debang Group to form syngas JV

Chemweeks business daily group

首页> 外文期刊>Chemweek's business daily >Air Products, Debang Group to form syngas JV

【24h】

Air Products, Debang Group to form syngas JV

机译：空气产品，Debang Group形成合成气JV

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Air Products and Jiangsu Debang Chemical Industrial Group have announced a plan to form a joint venture (JV) to own and operate a coal-to-syngas processing facility at Xuwei National Petrochemical Park in Jiangsu province, China. Air Products will own 80% of the JV, and Debang will own 20%. The JV will own and operate an air separation unit, and gasifcation and purifcation assets, under a 20-year contract for a fxed monthly fee.

机译：空气产品和江苏德邦化学工业集团宣布制定了一个组建合资企业（JV）的计划，拥有并在中国江苏省徐威国家石化公园运营煤炭到合成气加工机构。空气产品将拥有80％的JV，德邦将拥有20％。 JV将拥有并经营空中分离单元，并在20年的合同下进行空气分离单元，喘息和净化资产，以获得寄生费。

著录项

来源
《Chemweek's business daily》 |2019年第10期|共1页
作者
Chemweeks business daily group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类化学工业;
关键词

相似文献

外文文献
中文文献
专利

1. Air Products Forms JV with Debang Xinghua For New Coal-to-Syngas Facility in China [J] . PetroChemical News Group PetroChemical News . 2019,第35期

机译：Air Products与Debang Xinghua一起形成JV，用于中国新的煤炭到合成气体设施
2. Air Products, Debang to build syngas plant in China [J] . Al Greenwood ICIS News . 2019,第Sepa9期

机译：空气产品，Debang在中国建造合成气厂
3. Air Products forms $3.5-billion syngas JV [J] . Chemweeks business daily Group Chemweek's business daily . 2017,第Nova9期

机译：空气产品形成35亿美元合成气JV
4. HYDROGEN PRODUCTION FROM PLASMA-GENERATED SYNGAS: A DEMONSTRATION TEST USING IET'S PEM? AND AIR PRODUCTS' PRISM? H2 PSA SYSTEM [C] . NHA Annual Hydrogen Conference . 2007

机译：从等离子体产生的合成气产生氢气：使用IET的PEM进行演示测试？和空气产品的棱镜？ H2 PSA系统
5. Nox Formation in Syngas/Air Combustion [D] . Asgari, Nazli. 2018

机译：合成气/空气燃烧中的NOx形成
6. Products of Oxidative Guanine Damage Form Base Pairs with Guanine [O] . Katsuhito Kino, Taishu Kawada, Masayo Hirao-Suzuki, 2020

机译：氧化鸟嘌呤损伤的产品与鸟嘌呤碱基对
7. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)44The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur.55This document was approved by the American College of Cardiology Foundation Board of Trustees in July, 2003, the American Heart Association Science Advisory and Coordinating Committee in July, 2003, and the American Society of Nuclear Cardiology Board of Directors in July, 2003.66When citing this document, the American College of Cardiology Foundation, the American Heart Association, and the American Society of Nuclear Cardiology request that the following citation format be used: Klocke FJ, Baird MG, Bateman TM, Berman DS, Carabello BA, Cerqueira MD, DeMaria AN, Kennedy JW, Lorell BH, Messer JV, O’Gara PT, Russell RO Jr, St. John Sutton MG, Udelson JE, Verani MS, Williams KA. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). J Am Coll Cardiol 2003;42:1318–33.77(J Am Coll Cardiol 2003;42:1318–33)88©2003 by the American College of Cardiology Foundation and the American Heart Association, Inc. [O] . Klocke Francis J, Baird Michael G, Lorell Beverly H, 2003

机译：ACC / AHA / ASNC心脏放射性核素成像临床使用指南-执行摘要美国心脏病学会/美国心脏协会实践指南工作组的报告（ACC / AHA / ASNC委员会，对1995年临床使用指南进行修订ACC / AHA实践指导小组）竭尽全力避免由于写作小组成员的外部关系或个人利益而引起的任何实际或潜在的利益冲突。具体来说，要求写作小组的所有成员提供所有可能被视为实际或潜在利益冲突的关系的披露声明。这些声明由上级工作组审查，在第一次会议上向书面小组的所有成员口头报告，并在发生变化时进行更新。55本文件于2003年7月获得美国心脏病学会基金会董事会的批准。 2003年7月，美国心脏协会科学咨询与协调委员会，2003年7月，美国核心脏病学会理事会。66引用该文件时，美国心脏病学会基金会，美国心脏协会和美国核学会心脏病学要求使用以下引用格式：Klocke FJ，Baird MG，Bateman TM，Berman DS，Carabello BA，Cerqueira MD，DeMaria AN，Kennedy JW，Lorell BH，Messer JV，O'Gara PT，Russell RO Jr，St John Sutton MG，Udelson JE，Verani MS，Williams KA。 ACC / AHA / ASNC心脏放射性核素成像临床使用指南-执行摘要：美国心脏病学会/美国心脏协会实践小组工作指南（ACC / AHA / ASNC委员会，修订1995年临床指南）的报告使用放射性核素成像）。 J Am Coll Cardiol 2003; 42：1318–33.77（J Am Coll Cardiol 2003; 42：1318–33）88©2003美国心脏病学会基金会和美国心脏协会版权所有。
8. Nature of, and the Formaldehyde off-Gassing Characteristics of, Urea-Formaldehyde Foam Insulation (UFFI). Final Report to the Canadian Department of Consumer and Corporate Affairs: Product Safety Branch [R] . Gammage, R. B. 1981

机译：尿素 - 甲醛泡沫绝缘材料（UFFI）的性质和甲醛脱气特性。加拿大消费者和企业事务部的最终报告：产品安全处

Air Products, Debang Group to form syngas JV

摘要

著录项

相似文献

相关主题

期刊订阅